BMS-688521

BMS-688521 is a highly potent, orally active inhibitor of the LFA-1/ICAM interaction, with an IC50 of 2.5 nM in the adhesion assay and an IC50 of 60 nM in the MLR assay. BMS-688521 is efficacious in a mouse allergic eosinophilic lung inflammation model[1].

Product Specifications

CAS Number

[893397-44-9]

UNSPSC

12352005

Target

Integrin

Type

Reference compound

Related Pathways

Cytoskeleton

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/bms-688521.html

Concentration

10mM

Purity

98.62

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

ClC1=CC(Cl)=CC(N(C(N(C)[C@]23[C@H](C4=CC=C(C#N)C=C4)CN(C5=NC=C(C(O)=O)C=C5)C3)=O)C2=O)=C1

Molecular Formula

C26H19Cl2N5O4

Molecular Weight

536.37

References & Citations

[1]Watterson SH, et al. Small molecule antagonist of leukocyte function associated antigen-1 (LFA-1) : structure-activity relationships leading to the identification of 6- ((5S,9R) -9- (4-cyanophenyl) -3- (3,5-dichlorophenyl) -1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-7-yl) nicotinic acid (BMS-688521) . J Med Chem. 2010 May 13;53 (9) :3814-30.